S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
Critical asset just had biggest fall on record (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
Critical asset just had biggest fall on record (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
Critical asset just had biggest fall on record (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Stock market today: Another winning week for Wall Street ends with more records
Critical asset just had biggest fall on record (Ad)
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
One year after buying a failed bank, New York Community Bancorp is struggling
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations

Agiliti (AGTI) Competitors

$9.90
+0.03 (+0.30%)
(As of 03/1/2024 ET)

AGTI vs. EYPT, RLAY, ALHC, AHCO, SAGE, TARS, DCPH, AMLX, MIRM, and LMAT

Should you be buying Agiliti stock or one of its competitors? The main competitors of Agiliti include EyePoint Pharmaceuticals (EYPT), Relay Therapeutics (RLAY), Alignment Healthcare (ALHC), AdaptHealth (AHCO), Sage Therapeutics (SAGE), Tarsus Pharmaceuticals (TARS), Deciphera Pharmaceuticals (DCPH), Amylyx Pharmaceuticals (AMLX), Mirum Pharmaceuticals (MIRM), and LeMaitre Vascular (LMAT). These companies are all part of the "medical" sector.

Agiliti vs.

EyePoint Pharmaceuticals (NASDAQ:EYPT) and Agiliti (NYSE:AGTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.

EyePoint Pharmaceuticals currently has a consensus target price of $33.86, indicating a potential upside of 20.92%. Agiliti has a consensus target price of $14.17, indicating a potential upside of 43.10%. Given EyePoint Pharmaceuticals' higher probable upside, analysts plainly believe Agiliti is more favorable than EyePoint Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EyePoint Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Agiliti
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

EyePoint Pharmaceuticals has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Agiliti has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Agiliti has a net margin of -0.89% compared to Agiliti's net margin of -235.51%. EyePoint Pharmaceuticals' return on equity of 7.28% beat Agiliti's return on equity.

Company Net Margins Return on Equity Return on Assets
EyePoint Pharmaceuticals-235.51% -109.34% -47.39%
Agiliti -0.89%7.28%2.84%

EyePoint Pharmaceuticals received 405 more outperform votes than Agiliti when rated by MarketBeat users. Likewise, 69.73% of users gave EyePoint Pharmaceuticals an outperform vote while only 60.87% of users gave Agiliti an outperform vote.

CompanyUnderperformOutperform
EyePoint PharmaceuticalsOutperform Votes
447
69.73%
Underperform Votes
194
30.27%
AgilitiOutperform Votes
42
60.87%
Underperform Votes
27
39.13%

Agiliti has higher revenue and earnings than EyePoint Pharmaceuticals. Agiliti is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EyePoint Pharmaceuticals$42.52M31.00-$102.25M-$2.66-10.53
Agiliti$1.12B1.19$30.21M-$0.08-123.73

99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. 13.1% of EyePoint Pharmaceuticals shares are held by insiders. Comparatively, 4.5% of Agiliti shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Agiliti had 13 more articles in the media than EyePoint Pharmaceuticals. MarketBeat recorded 23 mentions for Agiliti and 10 mentions for EyePoint Pharmaceuticals. Agiliti's average media sentiment score of 0.66 beat EyePoint Pharmaceuticals' score of 0.45 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EyePoint Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Agiliti
6 Very Positive mention(s)
3 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

EyePoint Pharmaceuticals and Agiliti tied by winning 9 of the 18 factors compared between the two stocks.


Get Agiliti News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGTI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGTI vs. The Competition

MetricAgilitiequipment rental & leasing IndustryMedical SectorNYSE Exchange
Market Cap$1.33B$3.85B$5.03B$17.60B
Dividend YieldN/A1.96%2.81%3.58%
P/E Ratio-123.7318.53268.4525.25
Price / Sales1.192.173,026.429.54
Price / Cash4.616.4498.1916.96
Price / Book1.398.344.595.89
Net Income$30.21M$211.28M$114.92M$863.03M
7 Day Performance29.58%6.37%5.66%1.64%
1 Month Performance36.74%8.35%10.47%2.62%
1 Year Performance-47.23%4.61%13.91%106.03%

Agiliti Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EYPT
EyePoint Pharmaceuticals
2.8228 of 5 stars
$28.67
+8.0%
$33.86
+18.1%
+783.3%$1.35B$41.40M-10.78144Upcoming Earnings
Short Interest ↓
News Coverage
RLAY
Relay Therapeutics
1.5985 of 5 stars
$10.29
+1.3%
$24.17
+134.9%
-37.5%$1.35B$25.55M-3.68343
ALHC
Alignment Healthcare
3.0398 of 5 stars
$6.92
+11.4%
$10.70
+54.7%
-29.8%$1.31B$1.43B-8.141,037Earnings Report
Analyst Report
Short Interest ↓
Analyst Revision
News Coverage
AHCO
AdaptHealth
3.6125 of 5 stars
$10.00
+31.1%
$12.64
+26.4%
-30.5%$1.36B$3.08B-2.9210,900Analyst Report
Short Interest ↓
Analyst Revision
News Coverage
High Trading Volume
SAGE
Sage Therapeutics
4.2847 of 5 stars
$22.71
+0.4%
$41.59
+83.1%
-47.8%$1.37B$86.46M-2.51689Analyst Report
TARS
Tarsus Pharmaceuticals
3.6485 of 5 stars
$39.22
+18.3%
$43.20
+10.1%
+141.2%$1.30B$25.82M-10.2787Earnings Report
Analyst Report
Analyst Revision
News Coverage
Gap Down
High Trading Volume
DCPH
Deciphera Pharmaceuticals
3.9461 of 5 stars
$16.91
+2.9%
$22.60
+33.6%
+17.3%$1.37B$163.36M-7.38355Analyst Revision
News Coverage
AMLX
Amylyx Pharmaceuticals
4.6554 of 5 stars
$19.00
+8.2%
$38.33
+101.8%
-45.3%$1.29B$380.79M27.14374Short Interest ↓
MIRM
Mirum Pharmaceuticals
3.8918 of 5 stars
$29.61
+1.9%
$54.13
+82.8%
+23.5%$1.38B$77.06M-6.89249Analyst Report
Analyst Revision
News Coverage
LMAT
LeMaitre Vascular
2.7255 of 5 stars
$62.11
+0.7%
$67.60
+8.8%
+34.4%$1.38B$161.65M51.33591Earnings Report
Analyst Report
Analyst Revision
News Coverage

Related Companies and Tools

This page (NYSE:AGTI) was last updated on 3/2/2024 by MarketBeat.com Staff